10 results about "Hypertriglyceridemia" patented technology

This document describes the crystalline and liquid crystalline forms of sodium 25HC3S. This disclosure includes sodium 25HC3S in forms I, II, III, V, IX, XI, and XIII, and combinations thereof. Pharmaceutical formulations of the said forms or combinations thereof are further disclosed herein, as well as methods for treating or preventing diseases such as hypercholesterolemia, hypertriglyceridemia, and conditions associated with fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis). Methods for preparing 25HC3S are also provided.

The invention relates to a home management method and system for a patient with hypertriglyceridemia acute pancreatitis, and belongs to the technical field of data analysis. The method comprises the following steps: acquiring auxiliary analysis data of the patient; forming multi-modal sequence data in a time dimension based on the auxiliary analysis data; encoding the multi-modal sequence data based on a time sequence Transform of an attention mechanism, and generating a multi-modal feature vector; inputting the multi-modal feature vector into a risk prediction model, and outputting a deterioration risk probability of the patient; and outputting the health guidance of the patient based on the multi-modal feature vector. The multi-modal data is captured through an attention mechanism, the risk probability is quantified according to the multi-modal data, the potential deterioration risk can be perceived in the early stage, the recurrence and illness worsening risks are remarkably reduced, the health guidance is generated based on the individualized features of the patient, the health guidance is more suitable for the actual life of the patient, and the patient experience is improved. And the management participation and compliance of the patient are further improved.

This invention belongs to the field of biomedical technology, specifically relating to an isoflavone compound, its preparation method, and its application. This compound is derived from *Rotenoporosis capillaris* (a type of vine). Derris eriocarpa The stem of *Derris fusiforme* was analyzed using 1D and 2D nuclear magnetic resonance (NMR) spectra (1H NMR, 1C NMR, and high-resolution mass spectrometry), and its structural formula is shown below: Chemical name: 5-hydroxy-6-(2"-hydroxy-3"-methylbut-3"-enyl)-3-(4'-hydroxyphenyl)-7-methoxyisoflavone. Screening using the Sci-finder database revealed that this compound is a novel isoflavone, isolated for the first time from *Derris fusiforme*. Lipid-lowering activity experiments showed that at the same drug concentration (25 μg / mL) as the positive control, it significantly reduced intracellular total cholesterol and triglyceride levels. p <0.001). Therefore, this novel isoflavone compound can be used to prepare drugs, health products, functional foods, or special medical foods for the prevention or treatment of hypertriglyceridemia, hyperlipidemia, obesity, or metabolic syndrome.

The application discloses an aptamer for specifically distinguishing different glycosylation forms of ApoC-III, and a screening method and application thereof. The aptamer is specifically combined with non-glycosylated ApoC-III0, ApoC-III1, ApoC-III2, ApoC-III3 and total ApoC-III, and the nucleic acid sequence of the aptamer comprises any one or a combination of at least two of sequences shown in SEQ ID NO:1-SEQ ID NO:5. The aptamer has high affinity and strong specificity, can accurately distinguish the glycosylation spectrum of ApoC-III, and can be used for preparing a high-precision diagnostic kit for hypertriglyceridemia, atherosclerotic cardiovascular diseases and the like.

The present invention relates to an RNAi composition for inhibiting the expression of apolipoprotein C-III, and the use thereof. The RNAi composition can be used for treating and / or preventing APOC3-associated diseases or conditions such as cardiovascular diseases, hypertriglyceridemia and pancreatitis.

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

The present application provides a compound shown in formula I, wherein R1, R2, R3 are defined in the specification. The compound shown in formula I of the present application can effectively inhibit MOGAT2 enzyme activity, and has a clinical application prospect for treating and / or preventing obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, high VLDL, high fatty acid, diabetes or arteriosclerosis.

This disclosure relates to methods for using GLP-1 analogs and compositions thereof for the treatment of metabolic disorders such as obesity, diabetes mellitus, metabolic dysfunction-related fatty liver disease (MASLD), metabolic dysfunction-related steatohepatitis (MASH), and hypertriglyceridemia. More specifically, this disclosure relates to a method for treating obesity in a subject, comprising administering a therapeutically effective dose of GL0034 to the subject. This disclosure also relates to a method for treating a metabolic disorder in a subject requiring it, comprising administering a therapeutically effective dose of GL0034 to the subject. This disclosure further relates to compositions comprising GL0034 for the treatment of obesity, diabetes mellitus, or other metabolic disorders in a subject.

The present invention pertains to the field of nutraceuticals, specifically to a synergistic nutraceutical composition designed to improve cardio-metabolic health. The composition, comprising berberine, anthocyanin(s), and astaxanthin, is intended to regulate aberrant metabolic biomarkers, including hyperglycemia, hypertriglyceridemia, elevated low-density lipoprotein (LDL) cholesterol, increased blood pressure, enhanced platelet aggregation, elevated serum transaminase activity and hypoadiponectinemia. This invention is particularly applicable to the therapeutic management of cardiometabolic pathologies, including Type 2 Diabetes Mellitus (T2DM), arterial hypertension, dyslipidemia, atherosclerosis, obesity, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), cerebrovascular accidents (stroke), and coronary artery disease, through the modulation of systemic metabolic homeostasis and by providing potential adjunctive efficacy alongside established pharmacotherapeutic regimens.